发明申请
US20120308607A1 PRODUCTION AND USE OF HUMAN CD124- AND CD-116-POSITIVE TUMOR CELL LINES IN THE PRODUCTION OF ALLOGENIC OR SEMI-ALLOGENIC IMMUNOTHERAPY AGENTS
有权
人CD124和CD-116阳性肿瘤细胞系生产和使用生产同种异体免疫球蛋白
- 专利标题： PRODUCTION AND USE OF HUMAN CD124- AND CD-116-POSITIVE TUMOR CELL LINES IN THE PRODUCTION OF ALLOGENIC OR SEMI-ALLOGENIC IMMUNOTHERAPY AGENTS
- 专利标题（中）： 人CD124和CD-116阳性肿瘤细胞系生产和使用生产同种异体免疫球蛋白
-
申请号： US13553157申请日： 2012-07-19
-
公开(公告)号： US20120308607A1公开(公告)日： 2012-12-06
- 发明人: Steffen Goletz , Rik J. Scheper , Alan Masterson , Herbert M. Pinedo
- 申请人： Steffen Goletz , Rik J. Scheper , Alan Masterson , Herbert M. Pinedo
- 申请人地址： DE Berlin
- 专利权人： Glycotope GmbH.
- 当前专利权人： Glycotope GmbH.
- 当前专利权人地址： DE Berlin
- 优先权： DE10139428.4 20010817
- 主分类号： C12N5/0784
- IPC分类号： C12N5/0784 ; A61K35/12 ; A61P37/06 ; A61P35/00 ; A61P31/00 ; C12N5/16 ; A61P37/04
摘要：
The invention is related to the production and use of CD124+ and CD116+ cell lines for the production of effective dendritic cells (DC) using stimulatory molecules, their use in the production of allogenic or semi-allogenic immunotherapeutic agents and the use thereof in the treatment or prophylaxis of immune diseases. Furthermore, the invention is related to the use of CD124+ and CD116+ tumor cell lines, preferably also being CD34+, as model and yeast systems for testing the DC biology and for testing substances having an impact on the immune system and on the conditioning thereof.
公开/授权文献
- US09029143B2 MUTZ-3 dendritic cells 公开/授权日：2015-05-12
信息查询
